Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Approps Amendment Targets Chief Counsel Troy; Pfizer Ties Challenged

This article was originally published in The Tan Sheet

Executive Summary

The House FDA appropriations bill cuts $500,000 from the budget of the chief counsel's office in response to actions taken by Chief Counsel Daniel Troy

You may also be interested in...



House Democrats Take Plan B Battle To Appropriations Bill

An amendment intended to support the over-the-counter switch of emergency contraceptive Plan B (levonorgestrel) survived debate on the House floor July 13

House Democrats Take Plan B Battle To Appropriations Bill

An amendment intended to support the over-the-counter switch of emergency contraceptive Plan B (levonorgestrel) survived debate on the House floor July 13

House Democrats Take Plan B Battle To Appropriations Bill

An amendment intended to support the over-the-counter switch of emergency contraceptive Plan B (levonorgestrel) survived debate on the House floor July 13

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS097063

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel